These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 24770552

  • 1. Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors.
    Pastore S, Lulli D, Girolomoni G.
    Arch Toxicol; 2014 Jun; 88(6):1189-203. PubMed ID: 24770552
    [Abstract] [Full Text] [Related]

  • 2. IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity.
    Gangemi S, Franchina T, Minciullo PL, Profita M, Zanghì M, David A, Kennez I, Adamo V.
    J Cell Biochem; 2013 Dec; 114(12):2673-6. PubMed ID: 23794184
    [Abstract] [Full Text] [Related]

  • 3. Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors.
    Sinclair R.
    Asia Pac J Clin Oncol; 2014 Mar; 10 Suppl 1():11-7. PubMed ID: 24512509
    [Abstract] [Full Text] [Related]

  • 4. Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.
    Yamaki M, Sugiura K, Muro Y, Shimoyama Y, Tomita Y.
    Exp Dermatol; 2010 Aug; 19(8):730-5. PubMed ID: 20590818
    [Abstract] [Full Text] [Related]

  • 5. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
    Forsberg S, Ostman A, Rollman O.
    Arch Dermatol Res; 2008 Oct; 300(9):505-16. PubMed ID: 18446355
    [Abstract] [Full Text] [Related]

  • 6. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T, Landthaler M, Karrer S.
    Eur J Dermatol; 2007 Oct; 17(6):552-3. PubMed ID: 17951151
    [No Abstract] [Full Text] [Related]

  • 7. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4.
    Fischer A, Rosen AC, Ensslin CJ, Wu S, Lacouture ME.
    Dermatol Ther; 2013 Oct; 26(2):135-48. PubMed ID: 23551370
    [Abstract] [Full Text] [Related]

  • 8. Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin.
    Lulli D, Carbone ML, Pastore S.
    Oncotarget; 2016 Jul 26; 7(30):47777-47793. PubMed ID: 27322144
    [Abstract] [Full Text] [Related]

  • 9. Recent advances in the epidermal growth factor receptor/ligand system biology on skin homeostasis and keratinocyte stem cell regulation.
    Nanba D, Toki F, Barrandon Y, Higashiyama S.
    J Dermatol Sci; 2013 Nov 26; 72(2):81-6. PubMed ID: 23819985
    [Abstract] [Full Text] [Related]

  • 10. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
    Santoro F, Cozzani E, Parodi A.
    J Dermatolog Treat; 2006 Nov 26; 17(3):160-1. PubMed ID: 16854757
    [Abstract] [Full Text] [Related]

  • 11. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.
    Crit Rev Oncol Hematol; 2014 Feb 26; 89(2):284-99. PubMed ID: 24355409
    [Abstract] [Full Text] [Related]

  • 12. Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva).
    Lübbe J, Masouyé I, Dietrich PY.
    Dermatology; 2008 Feb 26; 216(3):247-9. PubMed ID: 18182820
    [Abstract] [Full Text] [Related]

  • 13. Cutaneous reactions to epidermal growth factor receptor inhibitors.
    Pomerantz RG, Mirvish ED, Geskin LJ.
    J Drugs Dermatol; 2010 Oct 26; 9(10):1229-34. PubMed ID: 20941947
    [Abstract] [Full Text] [Related]

  • 14. Cutaneous drug eruptions associated with the use of new oncological drugs.
    Belloni B, Schönewolf N, Rozati S, Goldinger SM, Dummer R.
    Chem Immunol Allergy; 2012 Oct 26; 97():191-202. PubMed ID: 22613863
    [Abstract] [Full Text] [Related]

  • 15. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.
    Clin Cancer Res; 2004 Oct 01; 10(19):6487-501. PubMed ID: 15475436
    [Abstract] [Full Text] [Related]

  • 16. Clinical research of EGFR inhibitors and related dermatologic toxicities.
    Perez-Soler R, Van Cutsem E.
    Oncology (Williston Park); 2007 Oct 01; 21(11 Suppl 5):10-6. PubMed ID: 18154213
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Epidermal growth factor receptor inhibitors in the treatment of nonmelanoma skin cancers.
    Khan MH, Alam M, Yoo S.
    Dermatol Surg; 2011 Sep 01; 37(9):1199-209. PubMed ID: 21615602
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.